Trial Profile
Radiographic patterns,Clinical course and risk factors of pneumonitis in patients with advanced non small cell lung cancer treated with pembrolizumab or nivolumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Nov 2017 New trial record
- 18 Oct 2017 Results assessing radiographic patterns, clinical course and risk factors of pneumonitis, presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 Results (n=134) presented at the 18th World Conference on Lung Cancer